Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of WarfarinAssessment of a Standardized Periprocedural Anticoagulation Regimen
نویسندگان
چکیده
Methods: We studied 650 consecutive patients with a mechanical heart valve, chronic atrial fibrillation, or embolic stroke who required interruption of warfarin therapy because of an invasive procedure. Warfarin was stopped 5 or 6 days before the procedure, and patients received subcutaneous dalteparin sodium, 100 IU/kg twice daily, starting 3 days before the procedure. The risk of postprocedural bleeding determined postprocedural anticoagulant management. In patients undergoing a non– high-bleeding-risk procedure who had adequate postprocedural hemostasis, warfarin was resumed on the evening of the procedure, and dalteparin sodium, 100 IU/kg twice daily, was resumed on the next day and continued until the international normalized ratio was 2.0 or more. If postprocedural hemostasis was not secured, the resumption of dalteparin was delayed. In patients undergoing a high-bleeding-risk procedure, warfarin was resumed on the evening of the procedure, but dalteparin was not given after the procedure.
منابع مشابه
Commentary. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
BACKGROUND The treatment of patients at increased risk for arterial thromboembolism who require temporary interruption of warfarin sodium therapy is a common clinical problem. We investigated the efficacy and safety of a standardized periprocedural anticoagulation regimen with low-molecular-weight heparin. METHODS We studied 650 consecutive patients with a mechanical heart valve, chronic atri...
متن کاملDVT: A New Era in Anticoagulant Therapy Periprocedural Anticoagulation Management of Patients With Venous Thromboembolism
Objective—Patients with venous thromboembolism (VTE) often require temporary warfarin interruption for an invasive procedure. The incidence of thromboembolism and bleeding related to periprocedural anticoagulation management of such patients is unknown. Methods and Results—In a protocol-driven, inception cohort design study, all VTE patients (n 775) referred for periprocedural anticoagulation m...
متن کاملSafety and efficacy of bridging with low molecular weight heparins: a systematic review and partial meta-analysis.
BACKGROUND Surgical interventions in patients on long term vitamin K antagonist (VKA) treatment create a dilemma; periprocedural interruption of anticoagulation raises the risk of thrombosis, while continuation raises the risk of bleeding. The anticoagulation- free interval is minimized by "bridging" with parenteral anticoagulants. The efficacy and safety of bridging with low molecular weight h...
متن کاملPeriprocedural anticoagulation management of patients with venous thromboembolism.
OBJECTIVE Patients with venous thromboembolism (VTE) often require temporary warfarin interruption for an invasive procedure. The incidence of thromboembolism and bleeding related to periprocedural anticoagulation management of such patients is unknown. METHODS AND RESULTS In a protocol-driven, inception cohort design study, all VTE patients (n=775) referred for periprocedural anticoagulation...
متن کاملSafety of novel oral anticoagulants in catheter ablation of atrial fibrillation.
INTRODUCTION Limited data are available regarding safety of catheter ablation of atrial fibrillation (AF) in patients using novel oral anticoagulants (NOAC) before and after pulmonary vein isolation. We aimed to assess the safety of a simple anticoagulation protocol in consecutive patients presenting for catheter ablation of AF. METHODS From November 2011 to December 2014, we prospectively in...
متن کامل